An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Launched by NGM BIOPHARMACEUTICALS, INC · Jun 13, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a medicine called NGM120 to see if it can help people with colorectal cancer who are also experiencing cancer cachexia. Cancer cachexia is a condition where someone loses a lot of weight and muscle, which can make them feel very weak and tired. The study is designed so that neither the participants nor the doctors know who is getting the medicine or a placebo (a “dummy” treatment), which helps make the results more reliable.

People who might join this study are adults with colorectal cancer who have experienced significant weight loss due to cachexia. To participate, they need to have a confirmed diagnosis of colorectal cancer and meet specific weight loss criteria. The study does not include people who have other causes of weight loss or those who are currently receiving feeding through tubes or intravenous nutrition. If eligible, participants will receive either NGM120 or a placebo, and their health will be closely monitored to see if the medicine helps with their weight and strength. The trial is not yet open for enrollment but will include men and women between the ages of 65 and 74.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Documented active diagnosis of colorectal cancer.
• • 2. Cachexia defined by Fearon criteria of weight loss.
• • 3. Signed informed consent.
• Exclusion Criteria:
• • 1. Current active reversible causes of decreased food intake.
• • 2. Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization.
• • 3. Have cachexia caused by other reasons.